PTLA News and Press, Portola Pharmaceuticals Inc. From 04/07/20

SOUTH SAN FRANCISCO, Calif. , April 7, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that the Centers for Medicare & Medicaid Services (CMS) established a new permanent J-code for Andexxa ® [coagulation factor Xa (recombinant), in...

SOUTH SAN FRANCISCO, Calif. , March 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced proactive steps the Company is taking in support of public heath efforts to prevent furtherspread of coronavirus (or COVID-19) around the globe. ...

SOUTH SAN FRANCISCO, Calif. , March 16, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced new data reinforcing the value of Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only FDA-approved reversal agent ...

Image source: The Motley Fool. Portola Pharmaceuticals Inc   (NASDAQ: PTLA) Q4 2019 Earnings Call Feb 26, 2020 , 4:30 p.m. ET Operator Continue reading

Portola Pharmaceuticals, Inc. (PTLA) Q4 2019 Earnings Conference Call February 26, 2020 04:30 PM ET Company Participants Jennifer Zibuda - Investor Relations Scott Garland - President and Chief Executive Officer Mardi Dier - Chief Financial and Chief Business Officer Sheldon ...

Portola Pharmaceuticals (NASDAQ: PTLA ): Q4 Non-GAAP EPS of -$0.75 beats by $0.03 ; GAAP EPS of -$1.24 misses by $0.36 . Revenue of $29.2M (+90.8% Y/Y) misses by $0.04M . Press Release More news on: Portola Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks new...

SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the fourth quarter and full year ended December 31, 2019. "2019 was a year of significant accomplishments for Portola ...

Portola Pharmaceuticals (NASDAQ: PTLA ) is scheduled to announce Q4 earnings results on Wednesday, February 26th, after market close. The consensus EPS Estimate is -$0.78 (+25.0% Y/Y) and the consensus Revenue Estimate is $29.24M (+91.1% Y/Y). Over the last 2 years, PTLA has beaten EP...

SOUTH SAN FRANCISCO, Calif. , Feb. 12, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the fourth quarter and full year ended December 31, 2019 , and p...

New York, New York--(Newsfile Corp. - February 11, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) ("Portola" or the "Company") of the March 16, 2020 deadline to seek the role of lead plaintiff in a fed...